
SP14019 – CYCLATOP


PILOT STUDY TO ASSESS EFFICACY AND SAFETY OF 5% TOPICAL CYCLOSPORINE A IN ATOPIC DERMATITIS

MAIN RESULTS

EASI. Percentage Change From Baseline

EASI MRMM model. Intraindividual analysis


Differences of treat LS Means



- 51.2% reduction of EASI baseline after 4 weeks
- Clinically relevant and statistically different to placebo from week 1 to end of treatment

ADSI. Percentage Change From Baseline

ADSI MRMM model. Intraindividual analysis
Differences of treat LS Means




* p<0.05

- 55.4% reduction of ADSI baseline after 4 weeks
- Clinically relevant and statistically different to placebo from week 1 to end of treatment

IGA. Change from baseline.

IGA GEE Model. Intraindividual analysis
Differences of treat LS Means

IGA ODDS ratio PP population



- Reduction of IGA has a statistically significant **ODDS Ratio ≈ 3** for all visits vs placebo
- **61.5 %** Patients reached IGA 0/1 at week 4